Cytokine production and serum levels in systemic sclerosis
- 31 December 1992
- journal article
- Published by Elsevier BV in Clinical Immunology and Immunopathology
- Vol. 65 (3), 278-285
- https://doi.org/10.1016/0090-1229(92)90158-k
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Lymphokine‐activated killer cell and natural killer cell activities in patients with systemic sclerosisArthritis & Rheumatism, 1992
- Fibrogenic cytokines: the role of immune mediators in the development of scar tissueImmunology Today, 1991
- Enhanced Production Of Interleukin‐1 And Tumor Necrosis Factor α By Cultured Peripheral Blood Monocytes From Patients With SclerodermaArthritis & Rheumatism, 1990
- Soluble interleukin‐2 receptors in patients with systemic sclerosisArthritis & Rheumatism, 1990
- The cytokine networkImmunology Today, 1989
- Native interleukin 1 inhibitorsImmunology Today, 1989
- Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysisEuropean Journal of Immunology, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneThe New England Journal of Medicine, 1987
- Inhibition of excessive scleroderma fibroblast collagen production by recombinant γ‐interferon: Association with a coordinate decrease in types I and III procollagen messenger RNA levelsArthritis & Rheumatism, 1986
- Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.The Journal of Experimental Medicine, 1986